Showing results (1-10 of 202) with videos related to

Sort By:
Pageof 21
Current Drug Targets. CNS and Neurological Disorders|February 18, 2004
5-HT1 receptorsLaurence Lanfumey, Michel Hamon
Therapie|January 26, 2006
[Neurobiology of depression: new data]Laurence Lanfumey, Michel Hamon
Neural Plasticity|July 21, 2007
Hippocampal neurogenesis, depressive disorders, and antidepressant therapyEleni Paizanis, Michel Hamon, Laurence Lanfumey
Medecine Sciences : M/S|December 8, 2004
[Alcohol dependence and polymorphisms of serotonin-related genes]Philip Gorwood, Laurence Lanfumey, Michel Hamon
Pharmacology & Therapeutics|January 26, 2013
Biological rhythms and melatonin in mood disorders and their treatmentsLaurence Lanfumey, Raymond Mongeau, Michel Hamon
Neuropharmacology|April 24, 2012
Early exposure to ethanol differentially affects ethanol preference at adult age in two inbred mouse strainsJenny Molet, Elodie Bouaziz, Michel Hamon, et al.
Neuroscience and Biobehavioral Reviews|June 7, 2008
Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disordersLaurence Lanfumey, Raymond Mongeau, Charles Cohen-Salmon, et al.
Neuroscience and Biobehavioral Reviews|March 18, 2014
Controversies on the role of 5-HT(2C) receptors in the mechanisms of action of antidepressant drugsCedric B P Martin, Michel Hamon, Laurence Lanfumey, et al.
Neurochemical Research|April 5, 2007
Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulationsEleni Paizanis, Sabah Kelaï, Thibault Renoir, et al.
Neuropharmacology|September 24, 2004
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brainNaïma Hanoun, Elisabeth Mocaër, Pierre-Alain Boyer, et al.
Pageof 21